Clinical Trial Update: Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the combination of bortezomib and azacitidine in adults with relapsed or refractory T-cell lymphomas; the trial is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Angioimmunoblastic T-cell Lymphoma
• Extranodal Nk T-cell Lymphoma Nasal Type
• Hepatosplenic T-cell Lymphoma
• Mycosis Fungoides Sezary Syndrome
• Peripheral T-cell Lymphoma
• T-cell Large Granular Lymphocytic Leukemia
• T-cell Leukemia Lymphoma

Drugs mentioned

• Bortezomib (Velcade) (Bortezomib)
• VIDAZA (AZACITIDINE)

Snippet

Sponsor: Pierluigi Porcu | Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Status: COMPLETED